Trends in Therapeutic Conjugates: Bench to Clinic

Rudra, Arnab; Li, Junwei; Shakur, Rameen; Bhagchandani, Sachin; Langer, Robert

doi:10.1021/acs.bioconjchem.9b00828

Cited by 22 publications

(19 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, nucleic acid therapeutics, such as small interfering RNAs (siRNA), small activating RNAs (saRNA), and messenger RNA (mRNA), have gained much traction and have been at the forefront of medicine with their potential in delivery efficiency and treatment of a wide range of diseases [ 87 , 88 ]. However, these genetic drugs are prone to rapid degradation by serum endonucleases.…”

Section: Lipid-based Nanoparticles For Gene Therapymentioning

confidence: 99%

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

et al. 2021

View full text Add to dashboard Cite

COVID-19 vaccines have been developed with unprecedented speed which would not have been possible without decades of fundamental research on delivery nanotechnology. Lipid-based nanoparticles have played a pivotal role in the successes of COVID-19 vaccines and many other nanomedicines, such as Doxil® and Onpattro®, and have therefore been considered as the frontrunner in nanoscale drug delivery systems. In this review, we aim to highlight the progress in the development of these lipid nanoparticles for various applications, ranging from cancer nanomedicines to COVID-19 vaccines. The lipid-based nanoparticles discussed in this review are liposomes, niosomes, transfersomes, solid lipid nanoparticles, and nanostructured lipid carriers. We particularly focus on the innovations that have obtained regulatory approval or that are in clinical trials. We also discuss the physicochemical properties required for specific applications, highlight the differences in requirements for the delivery of different cargos, and introduce current challenges that need further development. This review serves as a useful guideline for designing new lipid nanoparticles for both preventative and therapeutic vaccines including immunotherapies.

show abstract

Section: Lipid-based Nanoparticles For Gene Therapymentioning

confidence: 99%

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Furthermore, it could be anticipated that through integrating appropriate specific recognition elements with the plasmonic gold nanostructures, multiplex detection of various interested analytes that is of great demands and broad prospects will be realized. Much efforts should be made to transfer the biosensing and bioimaging assays from lab bench to clinic [ 104 ]. In this respect, developing biosensing and bioimaging systems that possess good anti-interference ability as well as longer period of validity, it is highly required.…”

Section: Conclusion and Outlooksmentioning

confidence: 99%

“…Much efforts should be made to transfer the biosensing and bioimaging assays from lab bench to clinic [ 104 ]. In this respect, developing biosensing and bioimaging systems that possess good anti-interference ability as well as longer period of validity, it is highly required.…”

Section: Conclusion and Outlooksmentioning

confidence: 99%

Plasmonic gold nanostructures for biosensing and bioimaging

Liu

Zhang

et al. 2021

Microchim Acta

View full text Add to dashboard Cite

Graphical abstract As one kind of noble metal nanostructures, the plasmonic gold nanostructures possess unique optical properties as well as good biocompatibility, satisfactory stability, and multiplex functionality. These distinctive advantages make the plasmonic gold nanostructures an ideal medium in developing methods for biosensing and bioimaging. In this review, the optical properties of the plasmonic gold nanostructures were firstly introduced, and then biosensing in vitro based on localized surface plasmon resonance, Rayleigh scattering, surface-enhanced fluorescence, and Raman scattering were summarized. Subsequently, application of the plasmonic gold nanostructures for in vivo bioimaging based on scattering, photothermal, and photoacoustic techniques has been also briefly covered. At last, conclusions of the selected examples are presented and an outlook of this research topic is given.

show abstract

“…The GalNAcconjugated Givlaari binds to the asialoglycoprotein receptors that are greatly expressed on normal hepatocytes. Moreover, numerous siRNA drug candidates are in the late stages of clinical trials [18][19][20].…”

Section: Introductionmentioning

confidence: 99%

Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics

Gangopadhyay

Nikam

Gore

2021

Nucleic Acid Therapeutics

View full text Add to dashboard Cite

RNA interference (RNAi), a gene regulatory process mediated by small interfering RNAs (siRNAs), has made remarkable progress as a potential therapeutic agent against various diseases. However, RNAi is associated with fundamental challenges such as poor systemic delivery and susceptibility to the nucleases. Targeting ligand-bound delivery vehicles has improved the accumulation of drug at the target site, which has resulted in high transfection efficiency and enhanced gene silencing. Recently, folate receptor (FR)-mediated targeted delivery of siRNAs has garnered attention due to their enhanced cellular uptake and high transfection efficiency toward tumor cells. Folic acid (FA), due to its small size, low immunogenicity, high in vivo stability, and high binding affinity toward FRs, has attracted much attention for targeted siRNA delivery. FRs are overexpressed in a large number of tumors, including ovarian, breast, kidney, and lung cancer cells. In this review, we discuss recent advances in FA-mediated siRNA delivery to treat cancers and inflammatory diseases. This review summarizes various FA-conjugated nanoparticle systems reported so far in the literature, including liposome, silica, metal, graphene, dendrimers, chitosan, organic copolymers, and RNA nanoparticles. This review will help in the design and development of potential delivery vehicles for siRNA drug targeting to tumor cells using an FR-mediated approach.

show abstract

Trends in Therapeutic Conjugates: Bench to Clinic

Cited by 22 publications

References 134 publications

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

Plasmonic gold nanostructures for biosensing and bioimaging

Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics

Contact Info

Product

Resources

About